Sumatriptan: update and review

Bibliography

• LIPTON RB, STEWART WF, DIAMOND S, DIAMOND ML, REED M: Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache (2001) 41(7):646-657.
   PubMed Web of Science ®Google Scholar
• SCHER AI, STEWART WF, LIPTON RB: Epidemiology of chronic daily headache. In: Chronic Daily Headache for Clinicians. Goadsby PJ, Silberstein SD, Dodick DW (Eds). BC Decker, Inc., Hamilton, Ontario (2005):3-11.
   Google Scholar
• STANG P, CADY R, BATENHORST A, HOFFMAN L: Workplace productivity. A review of the impact of migraine and its treatment. Pharmacoeconomics (2001)18(3):231-244.
   Google Scholar
• LIVEING E: Megrim, Sick Headache, and Some Allied Disorders: A Contribution to the Pathology of Nerve-Storms. Churchill (1873).
   Google Scholar
• SACKS O: Migraine: Understanding a Common Disorder. University of California Press, Berkley (1985):1-8, 228.
   Google Scholar
• WOLFF HG: Headache and Other Head Pain, 2nd Edn. Oxford University Press, New York, NY (1963).
   Google Scholar
• GARNER HH, SHULMAN B, MACNEAL PS, DIAMOND S: Psychiatric aspects of headache. Headache (1967) 7(1):1-12.
   Google Scholar
• LANCE JW, ANTHONY M, GONSKI A: Serotonin, the carotid body, and cranial vessels in migraine. Arch. Neurol. (1967) 16(5):553-558.
   PubMedGoogle Scholar
• SICUTERI F, ANSELMI B, FANCIULLACCI M: The serotonin (5-HT) theory of migraine. Neurology (1974) 4:383-394.
   Google Scholar
• HUMPHREY PPA, FENIUK W, PERREN MJ, CONNOR HE, OXFORD AW, COATS IH: GR43175, a selective agonist for the 5-HT-1-like receptor in dog saphenous vein. Br. J. Pharmacol. (1988) 94:1123-1132.
   PubMed Web of Science ®Google Scholar
• MOSKOWITZ MA, BUZZI MG: Evidence for 5-HT1B/1D receptor mediating the antimigraine effect of sumatriptan and dihydroergotamine. Cephalalgia (1991) 11:165-168.
   PubMedGoogle Scholar
• MOSKOWITZ MA: Neurogenic inflammation in the pathophysiology and treatment of migraine. Neurology (1993) 43(Suppl. 3):S16-S20.
   PubMed Web of Science ®Google Scholar
• OLESEN J, DIENER HC, HUSSTEDT IW, GOADSBY PJ, HALL D, MEIER U: Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N. Engl. J. Med. (2004) 350(11):1104-1110.
   PubMed Web of Science ®Google Scholar
• KAUBE H, HOSKIN K, GOADSBY PJ: Inhibition by sumatriptan of central trigeminal neurons only after blood-brain barrier disruption. Br. J. Pharmacol. (1993) 109:788-792.
   PubMed Web of Science ®Google Scholar
• BURSTEIN R, JAKUBOWSKI M, LEVY D: Anti-migraine action of triptans is preceded by transient aggravation of headache caused by activation of meningeal nociceptors. Pain (2005) 115(1-2):21-28.
   PubMed Web of Science ®Google Scholar
• CADY RK, ADELMAN J, TAYLOR F, BOUDREAU G, FEW C, WEBSTER C: Speed of onset and efficacy of sumatriptan fast-disintegrating/rapid –release tablets: results of a randomised, placebo-controlled study conducted in the USA and Canada. Headache Care (2004) 1(4):281-284.
   Google Scholar
• WALLS C, LEWIS A, BULLMAN J et al.: Pharmacokinetic profile of a new form of sumatriptan tablets in healthy volunteers. Curr. Med. Res. Opin. (2004) 20(6):803-809.
   Google Scholar
• FOWLER PA, LACEY LF, THOMAS M, KEENE ON, TANNER RJN, BABER NS: The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Eur. Neurol. (1991) 31:291-294.
   PubMed Web of Science ®Google Scholar
• PEROUTKA SJ: Sumatriptan in acute migraine: pharmacology and review of world experience. Headache (1990) 30(Suppl. 2):554-560.
   Google Scholar
• MACINTYRE PD, BHARGAVA B, HOGG KJ, GEMMILL JD, HILLIS WS: Effect of subcutaneous sumatriptan, a selective 5HT1 agonist, on the systemic, pulmonary, and coronary circulation. Circulation (1993) 87(2):401-405.
   PubMed Web of Science ®Google Scholar
• SCOTT AK, WALLEY T BRECKENRIDGE AM, LACEY LF, FOWLER PA: Lack of interaction between propanolol and sumatriptan. Br. J. Pharmacol. (1991) 32:581-584
   Google Scholar
• VAN HECKEN AM, DEPRE M, DE SCHEPPER PJ, FOWLER PA, LACEY LF, DURHAM JM: Lack of effect of flunarinizine on the pharmacokinetics and pharmacodynamics of sumatriptan in healthy volunteers. Br. J. Pharmacol. (1992) 34:82-84.
   Google Scholar
• SCOTT AK: Sumatriptan clinical pharmacokinetics. Clin. Pharmacokinet. (1994) 27(5):337-344.
   PubMed Web of Science ®Google Scholar
• BLIER P, BERGERON R: The safety of concomitant use of sumatriptan and antidepressant treatments. J. Clin. Psychopharmacol. (1995) 15:106-109.
   PubMed Web of Science ®Google Scholar
• LEUNG M: Lack of an interaction between sumatriptan and selective serotonin reuptake inhibitors. Headache (1995) 35:488-489.
   PubMed Web of Science ®Google Scholar
• CADY RK, WENDT JK, KIRCHNER JR,SARGENT JD, ROTHROCK JF, SKAGGS H: Treatment of acute migraine with subcutaneous sumatriptan. JAMA (1991) 265:2831-2835.
   PubMed Web of Science ®Google Scholar
• THE SUBCUTANEOUS SUMATRIPTAN INTERNATIONAL STUDY GROUP: Subcutaneous sumatriptan in the acute treatment of migraine. N. Engl. J. Med. (1991) 325:316-321.
   PubMed Web of Science ®Google Scholar
• HEADACHE CLASSIFICATION COMMITTEE OF THE INTERNATIONAL HEADACHE SOCIETY: Classification and diagnostic citeria for headache disorders, cranial neuralgias, and facial pain. Cephalalgia (1988) 8(Suppl.):18-28.
   Google Scholar
• CADY RC, RYAN R, JHINGRAN P, O’QUINN S, PAIT DG: Sumatriptan injection reduces productivity loss during a migraine attack. results of a double-blind, placebo-controlled trial. Arch. Int. Med. (1998) 158(9):1013-1018.
   PubMed Web of Science ®Google Scholar
• SCHULMAN EA, CADY RK, HENRY D: Effectiveness of sumatriptan in reducing productivity loss due to migraine: results of a randomized, double-blind, placebo-controlled clinical trial. Mayo Clin. Proc. (2000) 75:782-789.
   PubMed Web of Science ®Google Scholar
• WENDT J, CADY R, SINGER R et al.: A randomized, double-blind, placebo-controlled trial of the efficacy and tolerability of a 4-mg dose of subcutaneous sumatriptan for the treatment of acute migraine attacks in adults. Clin. Ther. (2006) 28(4):517-526.
   PubMed Web of Science ®Google Scholar
• DIAMOND S, ELKIND A, JACKSON T, RYAN R, DEBUSSEY S, ASGHARNEJAD M: Multiple-attack efficacy and tolerability of sumatriptan nasal spray in the treatment of migraine. Arch. Fam Med. (1998) 7:234-240.
   PubMedGoogle Scholar
• PFAFFEHRATH V, CUNIN G, SJONELL G, PENDERGAST S: Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: defining the optimal doses of oral sumatriptan. Headache (1998) 38:184-190.
   Google Scholar
• SARGENT J, KIRCHNER JR, DAVIS R, KIRKHART B: Oral sumatriptan is effective and well tolerated for the acute treatment of migraine: results of a multicenter study. Neurology. (1995) 45(Suppl. 7):S10-S14.
   PubMed Web of Science ®Google Scholar
• CUTLER N, MUSHET GR, DAVIS R, CLEMENTS B, WHITCHER L: Oral sumatriptan for the acute treatment of migraine: evaluation of three dosage strengths. Neurology. (1995) 45(Suppl. 7):S5-S9.
   Web of Science ®Google Scholar
• DAHLÖF C, CADY R, POOLE AC, BRANDES J, FEW C, JONES M: Speed of onset and efficacy of sumatriptan fast-disintegrating rapid-release tablets: pooled results of two replicate, randomized, placebo-controlled studies. Headache Care (2004) 1(4):277-280.
   Google Scholar
• BRANDES JL, O’CARROLL PC, MANNIX LK, LENER SE, LITTLEFIELD D, ALEXANDER WJ: Therapeutic clinical benefits of a new single-tablet formulation of sumatriptan formulated with RT technology and naproxen sodium. Presented at the 12th Congress of the International Headache Society. Kyoto, Japan (2005).
   Google Scholar
• WINNER PK, CADY RK, RUOFF G, FRISHBERG BM, ZHANG Y, ALEXANDER JW: Long term safety and tolerability of a fixed single-tablet formulation of sumatriptan RT Technology™ and naproxen sodium in the acute treatment of migraine. Accepted for platform presentation American Headache Society.
   Google Scholar
• SILBERSTEIN SD, STARK S, DEROSSETT SE, TAYLOR D, MCDONALD SA, LENER S: Superior clinical benefits of a new single-tablet formulation of sumatriptan formulated with RT Technology™ and naproxen sodium. Presented at the American Academy of Neurology 58th Annual Meeting. San Diego, CA (2006) S35:001.
   Google Scholar
• CADY RK, LIPTON RB, HALL C, STEWART WF, O’QUINN S, GUTTERMAN D: Treatment of mild headache in disabled headache sufferers: results of the spectrum study. Headache (2000) 40:792-797.
   PubMed Web of Science ®Google Scholar
• WINNER P, MANNIX LK, PUTNAM G, MCNEAL S, KWONG J, O’QUINN S: Pain-free results with sumatriptan taken at the first sign of migraine pain: 2 randomized, double blind, placebo controlled studies. Mayo Clin. Proc. (2003) 78:1214-1222.
   PubMed Web of Science ®Google Scholar
• PASCUAL J, CABARROCAS X: Within-patient early versus delayed treatment of migraine attacks with the sooner the better. Headache (2002) 42(1):28-31.
   PubMed Web of Science ®Google Scholar
• BRANDES JL, KUDROW D, CADY R, TISEO PJ, SUN W, SIKES CR: Eletriptan in the early treatment of acute migraine: influence of pain intensity and time of dosing. Cephalalgia (2005) 25(9):735-742.
   PubMed Web of Science ®Google Scholar
• CADY RK, ELKIND A, GOLDSTEIN J, KEYWOOD C: Randomized, placebo-controlled comparison of early use of frovatriptan in a migraine attack versus dosing after the headache has become moderate or severe. Curr. Med. Res. Opin. (2004) 20(9):1465-1472.
   PubMed Web of Science ®Google Scholar
• CADY R, MARTIN V, MAUSKOP A, RODGERS A, HUSTAD CM, RAMSEY KE: Efficacy of rizatriptan 10 mg administered early in a migraine attack. Headache (submitted).
   Google Scholar
• FERRARI MD: Should we advise patients to treat migraine attacks early: methodologic issues. Eur. Neurol. (2005) 53(Suppl. 1):17-21.
   PubMed Web of Science ®Google Scholar
• TFELT-HANSEN P, BLOCK G, DAHLOF C, DIENER H-C, FERRARI MD, GOADSBY PJ: Guidelines for controlled trials of drugs in migraine:second edition. Cephalalgia (2000) 20:765-786.
   PubMed Web of Science ®Google Scholar
• BURSTEIN R, YARNITSKY D, GOOR-ARYEH I, RANSIL BJ, BAJWA ZH: An association between migraine and cutaneous allodynia. Ann. Neurol. (2000) 47:614-624.
   PubMed Web of Science ®Google Scholar
• LEVY D, JAKUBOWSKI M, BURSTEIN R: Disruption of communication between peripheral and central trigeminovascular neurons mediates the antimigraine action of 5HT 1B/1D receptor agonists. Proc. Natl Acad. Sci. USA (2004) 101:4274-4279.
   PubMed Web of Science ®Google Scholar
• BURSTEIN R, COLLINS B, JAKUBOWSKI M: Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann. Neurol (2004) 55:18-26.
   Google Scholar
• LIPTON RB, STEWART WF, CADY RK et al.: Sumatriptan for the range of headaches in migraine sufferers: results of the spectrum study. Recipient of 2000 Wolff Award. Headache (2000) 40:783-791.
   PubMed Web of Science ®Google Scholar
• LIPTON RB, CADY RK, STEWART WF, WILKS K, HALL C: Diagnostic lessons from the spectrum study. Neurology (2002) 58(9 Suppl. 6):S27-S31.
   Web of Science ®Google Scholar
• TEPPER SJ, CADY RK, DODICK D et al.: Oral sumatriptan for treatment of probable migraine: first randomized controlled study. Headache (2006) 46:1-10.
   Google Scholar
• The International Classification of Headache Disorders 2nd Edition. Cephalalgia (2004) 24(Suppl. 1):1-160.
   Web of Science ®Google Scholar
• CADY RK, SCHREIBER CP: Sinus headache or migraine? Considerations in making a differential diagnosis. Neurology (2002) 58(Suppl. 6):S10-S14.
   Google Scholar
• SCHREIBER CP, HUTCHINSON S, WEBSTER CJ, AMES M, RICHARDSON MS, POWERS C: Prevalence of migraine in patients with a history of self-reported or physician-diagnosed ‘sinus’ headache. Arch. Intern Med (2004) 164(16):1769-1772.
   PubMed Web of Science ®Google Scholar
• ISHKANIAN G, BLUMENTHAL H, POWERS C, WEBSTER C, RICHARDSON MS: Sumatriptan is effective in migraine presenting as sinus headache. Poster presentation at Headache Update 2002. Orlando, FL (2002).
   Google Scholar
• EKBOM K, MONSTAD I, PRUSINSKI A, COLE JA, NORONHA D: Subcutaneous sumatriptan in the acute treatment of cluster headache: a dose comparison study. Acta Neurol. Scand. (1993) 88:63-69.
   PubMed Web of Science ®Google Scholar
• HERSHEY AD, POWERS SW, LECATES S, BENITTI AL: Effectiveness of nasal sumatriptan in 5 – 12 year old children. Headache (2001) 41:693-697.
   PubMed Web of Science ®Google Scholar
• UEBERALL MA, WENZEL D: Intranasal sumatriptan for acute treatment of migraine in children. Neurology (1999) 52:1507-1513.
   PubMed Web of Science ®Google Scholar
• WINNER P, ROTHNER D, SAPER J et al.: A randomized, double-blind, placebo-controlled, study of sumatriptan nasal spray in the treatment of acute migraine in adolescents. Pediatrics (2000) 106:989-997.
   PubMed Web of Science ®Google Scholar
• WINNER P, ROTHNER D, WEBSTER C et al.: Randomized, double-blind, placebo-controlled study of sumatriptan nasal spray in adolescent migraineurs. Neurology (2004) 62(Suppl. 5):182.
   Google Scholar
• CURRAN MP, EVANS HC, WAGSTAFF AJ: Intrnasal sumatriptan in adolescents with migraine. CNS Drugs (2005) 18(4):335-343.
   Google Scholar
• HOUGHTON LA, FOSTER JM, WHORWELL PJ, MORRIS J, FOWLER P: Is chest pain after sumatriptan oesophageal in origin? Lancet (1994) 344:985-986.
   PubMed Web of Science ®Google Scholar
• BOSKA MD, WELCH KMA, SCHULTZ L, NELSON J: Effects of the anti-migraine drug sumatriptan on muscle energy metabolism: relationship to side-effects. Cephalalgia (2000) 20:39-44.
   PubMed Web of Science ®Google Scholar
• TANSEY MJB, PILGRIM AJ, MATIN PM: Long-term experience with sumatriptan in the treatment of migraine. Eur Neurol (1993) 33:310-315.
   PubMedGoogle Scholar
• WELCH KM, MATHEW NT, STONE P, ROSAMOND W, SAIERS J, GUTTERMAN D: Tolerability of sumatriptan: clinical trials and post marketing experience. Cephalalgia (2000) 20:687-695.
   PubMed Web of Science ®Google Scholar
• DODICK D, LIPTON RB, MARTIN V et al.: Triptan Cardiovascular Safety Expert Panel: Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache (2004) 44(5):414-425.
   PubMed Web of Science ®Google Scholar
• THE SUMATRIPTAN AND NARATRIPTAN PREGNANCY REGISTRY: Interim report, 1 January 1996 – 3O April 2006: data available from GlaxoSmithKline.
   Google Scholar
• HALE TW: Medications and Mother’s Milk, 11th edn. Pharmasoft Publishing, Amarillo, TX (2004).
   Google Scholar
• JHINGRAN P, CADY RK, RUBINO J, MILLER D, GRICE RB, GUTTERMAN DL: Improvement in health-related quality of life with sumatriptan treatment for migraine. J. Fam. Pract. (1996) 42:36-42.
   PubMed Web of Science ®Google Scholar
• CADY RK, RYAN R, JHINGRAN P, O’QUINN S, PATT G: Sumatriptan injection reduces productivity loss during a migraine attack. Arch. Intern. Med. (1998) 158:1013-1018
   PubMed Web of Science ®Google Scholar
• ADELMAN JU, SHARFMAN M, JOHNSON R, MILLER D, CLEMENTS B, PATT G: Impact of oral sumatriptan on workplace productivity, health related quality of life, healthcare use and patient satisfaction with medication in nurses with migraine. Am. J. Man. Care. (1996) 2:1407-1416.
   Google Scholar
• HALPERN MT, LIPTON RB, CADY RK, KWONG WJ, MARLO KO, BATENHORST AJ: Costs and outcomes of early versus delayed migraine treatment with sumatriptan. Headache (2002) 42(10):984-999.
   PubMed Web of Science ®Google Scholar